Shares of Novo Nordisk retreated 1.5% in Copenhagen trading on Thursday, closing at 237.90 Danish crowns, despite receiving U.S. regulatory approval for a higher-dose formulation of its blockbuster obesity medication Wegovy. The decline persisted throughout the session as investors weighed competitive developments from rival Eli Lilly and the imminent expiration of key patents in India that could open the door to lower-cost generic alternatives.
Regulatory Milestone Overshadowed by Market Pressures
The U.S. Food and Drug Administration granted clearance for Wegovy HD, a new 7.2-milligram weekly injection, through its National Priority Voucher program. This accelerated pathway reduced the typical 10-12 month review period to just one or two months. Clinical data from the 72-week STEP UP study demonstrated that patients receiving the higher dose achieved average weight loss of 20.7%, compared to 17.5% for those on the existing 2.4-mg formulation. Novo Nordisk plans to launch the enhanced treatment in the United States in April using a single-dose pen delivery system.
Novo Nordisk Chief Executive Officer Mike Doustdar emphasized that the approval enables the company to deliver "even greater weight loss of approximately 21%" for patients. However, market analysts tempered their enthusiasm. BMO Capital Markets analyst Evan Seigerman described the development as "a step in the right direction" but noted the pharmaceutical giant faces "an uphill battle" to regain market share from increasingly formidable competitors.
Competitive Landscape Intensifies
The approval announcement coincided with fresh competitive pressure from Eli Lilly, which released new phase 3 trial data for its investigational obesity drug retatrutide. The weekly injection, which targets three hormone receptors, demonstrated reductions in A1C levels of 1.7 to 2.0 points and decreased body weight by up to 15.3% in patients with type 2 diabetes. Scotiabank analyst Louise Chen characterized these results as the "highest weight-loss levels I've seen from an obesity drug to date," highlighting the intensifying rivalry in the lucrative obesity therapeutics market.
This competitive dynamic has significantly impacted Novo Nordisk's market position in recent months. On February 23, Reuters reported that the company's shares tumbled more than 16% after its next-generation obesity treatment candidate, CagriSema, underperformed against Lilly's competing drug in a direct head-to-head trial. These developments have forced a broader reassessment of the obesity drug market's valuation, with Jefferies analyst Michael Leuchten declaring last month that the once-hyped $150 billion market opportunity "is gone" amid falling prices and mounting competition.
Patent Expiry and Generic Threat
Adding to Novo Nordisk's challenges, the patent protecting semaglutide—the active compound in both Wegovy and diabetes medication Ozempic—expires in India this week. Reuters reports that over 40 domestic pharmaceutical manufacturers, including industry leaders Sun Pharma, Dr. Reddy's, Zydus, and Lupin, are preparing to launch more than 50 generic brands. This influx of competition is expected to dramatically reduce prices, with the monthly cost for the lowest dose potentially falling from approximately 11,000 rupees to between 3,000 and 5,000 rupees.
Independent analyst Salil Kallianpur cautioned that this proliferation of brands and subsequent price reductions could potentially drive misuse of the medication and may eventually prompt regulatory intervention. The patent expiration represents a significant threat to Novo Nordisk's pricing power in emerging markets and could establish a precedent for other regions as patents expire globally.
Financial Outlook and Investor Concerns
These competitive and pricing pressures have manifested in Novo Nordisk's financial guidance. On February 4, the company projected that both 2026 sales and operating profit could decline by up to 13%, citing lower realized prices, intense competition, and patent losses in certain markets outside the United States. Chief Financial Officer Karsten Munk Knudsen told Reuters that U.S. sales alone could fall somewhere in the "teens" percentage range.
The company has been working to reassure investors following a difficult February, but Thursday's stock performance suggests that regulatory approvals alone may not be sufficient to counteract broader market concerns about pricing erosion and competitive dynamics. The obesity drug market, once viewed as a near-monopoly opportunity for early entrants like Novo Nordisk, has rapidly evolved into a fiercely contested therapeutic area with multiple well-funded competitors.
As the pharmaceutical landscape continues to shift, Novo Nordisk faces the dual challenge of defending its established market position while advancing its pipeline to maintain long-term growth. The company's ability to navigate these headwinds while capitalizing on its recent regulatory success with higher-dose Wegovy will be closely watched by investors in the coming quarters.
